Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

New Treatment for Carcinoid Syndrome

Clinical Article

Telotristat is a new medication for the treatment of carcinoid syndrome diarrhoea. Carcinoid syndrome is a condition that develops in around 10% of people with a carcinoid tumour. Carcinoid tumours develop from enterochromaffin cells,…

Read more

PBS Changes for Pembrolizumab Listing

Drugline Volume 373

In addition to the discontinuation of pembrolizumab 50mg vials, Merck Sharp & Dohme have advised of some upcoming changes to the Pharmaceutical Benefits Scheme (PBS) listing for the 100mg/4mL vials. These changes affect the…

Read more

Updated Results for Pembrolizumab in treatment of metastatic non-small cell lung cancer

Drugline Volume 372

As discussed in Drugline Volume 354, pembrolizumab is available on the Pharmaceutical Benefits Scheme (PBS) for the first-line treatment of metastatic non-small cell lung cancer. In the original KEYNOTE-024 trial, the median duration follow up was…

Read more

Palbociclib added to the Pharmaceutical Benefits Scheme

Drugline Volume 371

Palbociclib has recently listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic breast cancer. Palbociclib is a selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. Cyclins and…

Read more

Faster-Acting Insulin Aspart

Drugline Volume 370

Fiasp® is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of diabetes mellitus. Fiasp® is a novel formulation of insulin aspart containing the excipients nicotinamide (vitamin B3) and arginine hydrochloride. Human…

Read more

Alemtuzumab Safety Review

Drugline Volume 369

The European Medicines Agency (EMA) has announced prescribing restrictions of alemtuzumab for multiple sclerosis (MS) while a safety review is undertaken. This action is in response to new reports of serious cardiovascular and immune-mediated…

Read more
Load More

August 2019

April 2019

New High-Strength Insulin (Apr. 18 2019)

Tofacitinib Safety Issue (Apr. 05 2019)

March 2019

February 2019

January 2019

December 2018

October 2018

September 2018

August 2018

July 2018

April 2018

January 2018

December 2017

September 2017

Thunderstorm Asthma (Sep. 21 2017)

The Efficacy of Perampanel (Sep. 08 2017)

July 2017

June 2017

April 2017

March 2017

November 2016

September 2016

August 2016

April 2016

November 2015

Viekira Pak for Hepatitis C (Nov. 19 2015)

Micafungin (Nov. 05 2015)

October 2015

Dabigatran Antidote on the Horizon (Oct. 22 2015)

Akynzeo® (Oct. 08 2015)

September 2015

May 2015

April 2015

Victoza (liraglutide) (Apr. 23 2015)

Ultibro Breezhaler 100/50 (Apr. 09 2015)

March 2015

February 2015

December 2014

November 2014

October 2014

September 2014

World Pharmacist Day (Sep. 24 2014)

National Stroke Week (Sep. 11 2014)

August 2014

July 2014

Breo™ Ellipta® (Jul. 31 2014)

Use of Prolia® in Men (Jul. 17 2014)

Adcetris® (brentuximab vedotin) (Jul. 03 2014)

April 2014

March 2014

September 2013

August 2013

July 2013

June 2013

Riluzole for Motor Neurone Disease (Jun. 20 2013)

Mycamine (Jun. 06 2013)

May 2013

HPV Vaccine (May. 23 2013)

World Lupus Day (May. 09 2013)

December 2012

November 2012

August 2012